{
  "meta": {
    "title": "33_Gbs",
    "url": "https://brainandscalpel.vercel.app/33-gbs-a64d4ff6.html",
    "scrapedAt": "2025-11-30T06:57:12.972Z"
  },
  "questions": [
    {
      "id": 61555,
      "choices": [
        {
          "id": 268332,
          "text": "Ataxia"
        },
        {
          "id": 268333,
          "text": "Areflexia of limbs"
        },
        {
          "id": 268334,
          "text": "Weakness of limbs"
        },
        {
          "id": 268335,
          "text": "Ophthalmoplegia"
        }
      ],
      "text": "Which of the following is not found in Miller Fisher syndrome?",
      "unique_key": "Q4756189",
      "question_audio": null,
      "question_video": null,
      "map_id": 34213527,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Weakness of limbs. Miller Fisher syndrome (MFS) is a variant of Guillain-Barré syndrome (GBS), and it is characterized by a specific set of neurological symptoms. These include: Ataxia: This is a hallmark of Miller Fisher syndrome, resulting from the involvement of the cerebellum or its pathways, leading to loss of coordination and balance. Areflexia of limbs: This is commonly seen in MFS, as the condition is associated with demyelination of peripheral nerves, resulting in absent reflexes, including in the limbs. Ophthalmoplegia: This refers to the paralysis or weakness of the eye muscles, which is a key feature of MFS. It affects the eye movements, particularly the extraocular muscles, leading to problems with eye movement. Weakness of limbs is not a typical feature of Miller Fisher syndrome. In contrast to other forms of Guillain-Barré syndrome, which commonly involve significant limb weakness due to motor nerve involvement, Miller Fisher syndrome is primarily characterized by ataxia, ophthalmoplegia, and areflexia, with minimal or no significant weakness of limbs. The lack of pronounced motor involvement in MFS is what distinguishes it from other types of GBS, like acute inflammatory demyelinating polyneuropathy (AIDP), where limb weakness is more common. Incorrect Answers: A. Ataxia: Ataxia is indeed found in Miller Fisher syndrome, as the condition often involves cerebellar dysfunction or disruption in the proprioceptive pathways leading to loss of coordination and balance. B. Areflexia of limbs: Areflexia is a common feature of Miller Fisher syndrome. The condition is characterized by absent reflexes in the limbs, which result from the demyelination of the peripheral nerves. D. Ophthalmoplegia: Ophthalmoplegia is another key feature of Miller Fisher syndrome. It refers to paralysis of the eye muscles, leading to impaired eye movement, particularly affecting horizontal and vertical gaze.",
      "correct_choice_id": 268334,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/13591261701702107/13591261701702107.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/13591261701702107/13591261701702107.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 61556,
      "choices": [
        {
          "id": 268336,
          "text": "GQ1a"
        },
        {
          "id": 268337,
          "text": "GQ1b"
        },
        {
          "id": 268338,
          "text": "GQ1c"
        },
        {
          "id": 268339,
          "text": "GQ1d"
        }
      ],
      "text": "Miller Fisher syndrome (MFS) is strongly associated with which of the following antibodies?",
      "unique_key": "Q8967353",
      "question_audio": null,
      "question_video": null,
      "map_id": 34195938,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) GQ1b Miller Fisher syndrome (MFS) is a rare, immune-mediated neurological disorder considered a variant of Guillain-Barré syndrome (GBS). It is classically characterized by a triad of ophthalmoplegia, ataxia, and areflexia. The hallmark of MFS is the strong association with anti-GQ1b antibodies, which are found in up to 85–90% of patients with the syndrome. GQ1b is a type of ganglioside, a glycosphingolipid present in high concentrations in cranial nerves, especially those that control eye movements. The presence of these antibodies is thought to mediate immune attack on the peripheral nerves, particularly affecting the oculomotor nerves and proprioceptive fibers, explaining the clinical features seen in MFS. Detection of anti-GQ1b antibodies can be a key diagnostic clue in patients presenting with the characteristic triad. Option A: GQ1a – Incorrect GQ1a is not commonly associated with Miller Fisher syndrome. While it is another ganglioside, it does not have a known strong link to the disease. Anti-GQ1a antibodies are not typically found in patients with MFS and do not play a diagnostic role. Option C: GQ1c – Incorrect GQ1c is not a recognized ganglioside involved in neurological syndromes like MFS. It is not relevant in the context of antibody associations with peripheral neuropathies. This answer option is likely a distractor. Option D: GQ1d – Incorrect GQ1d, like GQ1c, is not implicated in Miller Fisher syndrome. It is not involved in the immunopathogenesis of the disease and does not appear in the serological profile of MFS patients. Therefore, this is also an incorrect option.",
      "correct_choice_id": 268337,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/40314391701702118/40314391701702118.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/40314391701702118/40314391701702118.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 61557,
      "choices": [
        {
          "id": 268340,
          "text": "Bladder involvement occurs in severe cases"
        },
        {
          "id": 268341,
          "text": "Anti GD1a antibodies are found in patients of Acute Motor Axonal Neuropathy (AMAN) subtype of GBS"
        },
        {
          "id": 268342,
          "text": "Glucocorticoids are effective in GBS"
        },
        {
          "id": 268343,
          "text": "Facial diparesis found in 50% of cases"
        }
      ],
      "text": "Which of the following statements about Gullain-Barre syndrome (GBS) is false?",
      "unique_key": "Q4268304",
      "question_audio": null,
      "question_video": null,
      "map_id": 34142703,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Glucocorticoids are effective in GBS Glucocorticoids are not considered effective in the treatment of Guillain-Barré Syndrome (GBS). In fact, research has shown that steroids like glucocorticoids do not provide significant benefit in improving outcomes for patients with GBS. The mainstays of treatment for GBS are plasmapheresis (plasma exchange) and intravenous immunoglobulin (IVIG), both of which have been shown to reduce the severity of the illness and improve recovery time. Therefore, the use of glucocorticoids is not recommended as a first-line treatment in GBS. Incorrect Answers: A. Bladder involvement occurs in severe cases: Bladder dysfunction, including urinary retention or incontinence, can occur in severe cases of GBS, particularly when there is autonomic involvement. This is due to the effect of the disease on the autonomic nervous system, which controls bladder function. Severe cases of GBS may also involve other autonomic disturbances, such as blood pressure fluctuations and heart rate abnormalities. B. Anti GD1a antibodies are found in patients of Acute Motor Axonal Neuropathy (AMAN) subtype of GBS: Anti-GD1a antibodies are indeed commonly found in patients with the Acute Motor Axonal Neuropathy (AMAN) subtype of GBS. AMAN is characterized by motor axon involvement, and the presence of these antibodies helps to differentiate it from other GBS subtypes. This association makes anti-GD1a a key marker for the diagnosis of AMAN. D. Facial diparesis found in 50% of cases: Facial diparesis (weakness of both sides of the face) occurs in approximately 50% of GBS cases, particularly in the classic form of the disease. This bilateral facial weakness is a common symptom due to the involvement of cranial nerves, especially the facial nerve, in GBS. It can significantly contribute to the overall clinical presentation of the syndrome.",
      "correct_choice_id": 268342,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/3904461701702130/3904461701702130.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/3904461701702130/3904461701702130.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 61558,
      "choices": [
        {
          "id": 268344,
          "text": "Intravenous immunoglobulin"
        },
        {
          "id": 268345,
          "text": "Intravenous Methylprednisolone"
        },
        {
          "id": 268346,
          "text": "Intravenous Cyclophosphamide"
        },
        {
          "id": 268347,
          "text": "Rituximab"
        }
      ],
      "text": "Treatment of choice for GBS-",
      "unique_key": "Q2303134",
      "question_audio": null,
      "question_video": null,
      "map_id": 34592167,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Intravenous immunoglobulin The treatment of choice for Guillain-Barré Syndrome (GBS) is intravenous immunoglobulin (IVIG). IVIG is a blood product derived from pooled human plasma and is used to modulate the immune system. It has been shown to be effective in reducing the severity of GBS symptoms and speeding up recovery by inhibiting harmful autoantibodies that attack the peripheral nervous system. IVIG is commonly used in GBS patients, especially in the acute phase, and has proven to be both safe and effective in clinical trials. Incorrect Answers: B. Intravenous Methylprednisolone: Although steroids like intravenous methylprednisolone are commonly used in many autoimmune conditions, they are not effective in the treatment of GBS. Research has shown that glucocorticoids, including methylprednisolone, do not improve the prognosis of GBS and may even be harmful by impairing recovery. Thus, methylprednisolone is not a recommended treatment for GBS. C. Intravenous Cyclophosphamide: Cyclophosphamide is a potent immunosuppressive drug used in certain conditions like cancers and severe autoimmune disorders. However, it is not recommended for GBS. Its use in GBS is not supported by clinical evidence, and it carries significant risks, such as infections and organ toxicity. IVIG and plasmapheresis are preferred treatments over cyclophosphamide. D. Rituximab: Rituximab is a monoclonal antibody that targets CD20 on B cells and is primarily used in the treatment of B-cell lymphomas, certain autoimmune diseases, and refractory rheumatoid arthritis. While rituximab has been explored in the treatment of some autoimmune neuropathies, it is not a standard treatment for GBS. The efficacy and safety of rituximab in GBS have not been proven in clinical trials, making it an inappropriate choice for routine GBS treatment.",
      "correct_choice_id": 268344,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/26777481701702142/26777481701702142.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/26777481701702142/26777481701702142.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 61559,
      "choices": [
        {
          "id": 268348,
          "text": "Mycoplasma"
        },
        {
          "id": 268349,
          "text": "Epstein-Barr virus"
        },
        {
          "id": 268350,
          "text": "Chlamydia infection"
        },
        {
          "id": 268351,
          "text": "Campylobacter jejuni"
        }
      ],
      "text": "Which of the following is the most common antecedent infection associated with GBS?",
      "unique_key": "Q2214504",
      "question_audio": null,
      "question_video": null,
      "map_id": 34843120,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Campylobacter jejuni The most common antecedent infection associated with Guillain-Barré Syndrome (GBS) is Campylobacter jejuni. This bacterial infection, typically transmitted through contaminated food (especially undercooked poultry), is strongly linked to GBS. Campylobacter jejuni can trigger an immune response that leads to the development of GBS, particularly through molecular mimicry, where the immune system mistakenly attacks the peripheral nervous system due to similarities between the bacterial and neuronal components. It is the most commonly identified infection preceding GBS, accounting for a significant percentage of cases. Incorrect Answers: A. Mycoplasma: While Mycoplasma pneumoniae infection can occasionally precede GBS, it is much less commonly associated with the condition compared to Campylobacter jejuni. Mycoplasma infections are more frequently linked to other neurological complications, but they do not play as central a role in GBS as Campylobacter does. B. Epstein-Barr virus: Epstein-Barr virus (EBV) is another virus that has been reported in some cases of GBS, but it is not the most common antecedent infection. EBV is primarily associated with conditions such as infectious mononucleosis, and although it can trigger autoimmune responses, its role in GBS is less frequent than Campylobacter jejuni. C. Chlamydia infection: Chlamydia infections, specifically Chlamydia pneumoniae, have been investigated as potential triggers for GBS, but they are not as frequently associated as Campylobacter jejuni. While Chlamydia can cause respiratory infections and may rarely be linked to GBS, it is much less common than the bacterial and viral infections like Campylobacter and EBV in triggering the syndrome.",
      "correct_choice_id": 268351,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/66903591701702153/66903591701702153.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/66903591701702153/66903591701702153.m3u8",
      "question_images": [],
      "explanation_images": []
    }
  ]
}